[
1. Hadzi-Đokić BJ, Aćimović MŽ, Bašić DT. Selected chaptets from urology. Data status. Belgrade. 2020. pp 375-6;
]Search in Google Scholar
[
2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in European Union: cancer registry data and estimates of national incidence for 1990. EJC, 1997. 33: 1075-107.10.1016/S0959-8049(96)00492-3
]Search in Google Scholar
[
3. European Association of Urology. Availabe at: https://uroweb.org/guideline/prostate-cancer/Last visited: 20.07.2021.
]Search in Google Scholar
[
4. Huggins C, Hodges CV. Studies on prostate cancer: I. The effects of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research, 1941. 1: 293–7.
]Search in Google Scholar
[
5. Marušić G, Vojinov S, Levakov I. Treatmend of locally advanced prostatic cancer. Med review, 2010. 63(9-10).10.2298/MPNS1010689M21446100
]Search in Google Scholar
[
6. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and metaanalysis. Ann Intern Med, 2000. 132(7): 566–77.10.7326/0003-4819-132-7-200004040-0000910744594
]Search in Google Scholar
[
7. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomized comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 1998. 33(5): 447–5610.1159/0000196349643663
]Search in Google Scholar
[
8. Eisenberger MA, Blumenstein BA, Crawford ED, McLeod GD, Loehler PJ, Wilding G. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Eng J Med, 1998. 339(15): 1036–42.10.1056/NEJM1998100833915049761805
]Search in Google Scholar
[
9. Medicines and medical devices agency of Serbia. Consumption of medical devices. Available at: https://www.alims.gov.rs/eng/medical-devices/Last visited: 19.07.2021.
]Search in Google Scholar
[
10. Smiljanic MT,Radonjic V, Đurić D. Evaluation of antibiotic consumption at Rakovica community health center from 2011 to 2015. Ser J Exp Clin Res 2017. 18(3): 245-250.10.1515/sjecr-2016-0054
]Search in Google Scholar
[
11. World Health Organization. ATC/DDD index 2021. Available at: https://www.whocc.no/atc_ddd_index/. Last visited: 19.07.2021.
]Search in Google Scholar
[
12. Statistical office of the Republic of Serbia. Estimates of population. Available at: https://www.stat.gov.rs/en-US/oblasti/stanovnistvo Last visited: 19.07.2021.
]Search in Google Scholar
[
13. Institute of Public Health of Serbia dr Milan Jovanovic Batut. Health statistical year book of Rebublic of Serbia. Available at: https://batut.org.rs/index.php?category_id=132 Last visited: 19.07.2021.
]Search in Google Scholar
[
14. Agency for medicinal products and medical devices of Croatia. Medicinal products utilisation in Croatia from 2015. to 2019. Available at: https://halmed.hr/en/Novosti-i-edukacije/Publikacije-iizvjesca/Publikacije/Potrosnja-lijekova-u-Hrvatskoj-od-2015-do-2019-godine/19 Last visited: 19.07.2021.
]Search in Google Scholar
[
15. Italian Medicines Agency. L’uso dei farmaci in Italia. Available at: https://www.aifa.gov.it/en/usi-dei-farmaci-in-italila. Last visited: 19.07.2021.
]Search in Google Scholar
[
16. Leuprorelin 3,75mg. Summary of product characteristis. Medicines and Medical Devices Agency of Serbia. Available at: https://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-04365-14-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
17. Leuprorelin 11,25mg Summary of product characteristis.. Medicines and Medical Devices Agency of Serbia. Available at :https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-04366-14-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
18. Goserelin 3,6mg. Summary of product characteristis. Medicines and Medical Devices Agency of Serbia. Available at: https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-00677-17-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
19. Goserelin 10,8mg. Summary of product characteristis. Medicines and Medical Devices Agency of Serbia. Available at: https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-01159-13-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
20. Triptorelin 3,75mg. Summary of product characteristis. Medicines and Medical Devices Agency of Serbia. Available at: https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-01885-13-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
21. Triptorelin 11,25mg. Summary of product characteristis. Medicines and Medical Devices Agency of Serbia. Dostupno na: https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-01890-13-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
22. Triptorelin 22,5mg. Summary of product characteristis. Medicines and Medical Devices Agency of Serbia. Available at: https://www.alims.gov.rs/ciril/files/lekovi/pil/515-01-01890-13-001.pdf Last visited: 12.12.2021.
]Search in Google Scholar
[
23. WHO Colaborating Centre for Drug Statistics Methodology. ATC/DDD index. Available at: https://www.whocc.no/atc_ddd_index/?code=L02AE&showdescription=no. Last visited: 12.12.2021.
]Search in Google Scholar
[
24. Kuang-Ming Liao, Ya-Ling Wang, Chung-Yu Chen. Medication utilization evaluation of androgen deprivation therapy for prostate cancer in Taiwan. Medicine (Baltumure), 2020. 99 (50): 23644.10.1097/MD.0000000000023644773813333327345
]Search in Google Scholar
[
25. Nada B., Miroslav K., Svetislav J. Tretment of metastatic prostate cancer. Med Cigota, 2006. 11(19): 24-31.
]Search in Google Scholar
[
26. M. Shim, W.J. Bang, C.Y. Oh, Y.S. Lee, J.S. Cho. Effectiveness of three different luteinizing hormonereleasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investing Clin Urol, 2019. 60 (4): 244-50.10.4111/icu.2019.60.4.244660707431294133
]Search in Google Scholar
[
27. Axel S Merseburger et al. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. J. Comp. Eff. Res, 2015. 4(5): 447–45310.2217/cer.14.8225521079
]Search in Google Scholar
[
28. S. Lannzo, L. Pradelli L, M. Crasi, M. Perachino. Costeffecitveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value in health, 2011. 14: (1): 80-9.10.1016/j.jval.2010.10.02321211489
]Search in Google Scholar
[
29. Fourcade RO, Benedict A, Libby BA, Stokes EM, Alcaraz A, Castro R. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU, 2010. 105(1):49-56.10.1111/j.1464-410X.2009.08716.x20132102
]Search in Google Scholar
[
30. Orrason AW, Westeberg M, Garmo H, Lissabrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU, 2020. (126): 1. 142-151.10.1111/bju.1507732274889
]Search in Google Scholar
[
31. Alex MS, B.Thomas, W.James, M.Davide. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.J Comp Eff Res, 2015. 4(5): 447-453.10.2217/cer.14.8225521079
]Search in Google Scholar
